Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
3.590 USD   -2.18%
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $14
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

09/16/2022 | 07:24am EST

ADC Therapeutics SA and Swedish Orphan Biovitrum AB (Sobi) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion from the CHMP is now referred to the European Commission for an approval decision. Earlier this year, ADC Therapeutics announced an exclusive license agreement with Sobi to develop and commercialize ZYNLONTA for all hematologic and solid tumor indications in Europe and select international territories.

The opinion is based on data from LOTIS-2, a large (n=145) Phase 2 multinational, single-arm clinical trial of ZYNLONTA for the treatment of adult patients with relapsed or refractory DLBCL following two or more prior lines of systemic therapy. In April 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval of ZYNLONTA as the first CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. In September 2021, the European Commission granted Orphan Drug Designation to ZYNLONTA for the treatment of DLBCL.

ADC Therapeutics has an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. In addition, Overland ADCT BioPharma, a joint venture formed by Overland Pharmaceuticals and ADC Therapeutics, is working to develop and commercialize ZYNLONTA in greater China and Singapore. Overland ADCT BioPharma is now conducting a registrational pivotal Phase 2 clinical trial of ZYNLONTA in relapsed or refractory DLBCL in China.

ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.

The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADC THERAPEUTICS SA -2.18% 3.59 Delayed Quote.-82.23%
SWEDISH ORPHAN BIOVITRUM AB (PUBL) 0.74% 218 Delayed Quote.17.77%
All news about ADC THERAPEUTICS SA
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
11/09RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
11/08Transcript : ADC Therapeutics SA, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Revenue $76.3M
MT
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 EPS $0.13
MT
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
11/08ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/08ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Upd..
BU
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2022 196 M - -
Net income 2022 -159 M - -
Net cash 2022 309 M - -
P/E ratio 2022 -1,76x
Yield 2022 -
Capitalization 287 M 287 M -
EV / Sales 2022 -0,11x
EV / Sales 2023 0,80x
Nbr of Employees 312
Free-Float 46,9%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,59 $
Average target price 14,17 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Chief Scientific Officer
Joseph S. Camardo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-82.23%287
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930